Indolylmaleimide derivatives

US7220774B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Rainer Albert · Basel, CH
• Claus Ehrhardt · Lörrach, DE
• Jean-Pierre Evenou · La Valette-du-Var, FR
• Richard Sedrani · Basel, CH
• Peter Von Matt · Biel-Benken, CH
• Jurgen Wagner · Bottmingen, CH
• Gerhard Zenke · Rheinfelden (Baden), DE

Key dates

• Filing date: Sep 11, 2003
• Grant date: May 22, 2007
• Expiry date: Dec 18, 2023

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Indolylmaleimide derivatives comprising either a substituted phenyl, naphthyl, tetrahydronaphthyl, quinazolinyl, quinolyl, isoquinolyl or pyrimidinyl residue have interesting pharmaceutical properties, e.g. in the treatment and/or prevention of T-cell mediated acute or chronic inflammatory diseases or disorders, autoimmune diseases, graft rejection or cancer.